Evolus, Inc. (NASDAQ:EOLS) is Stonepine Capital Management LLC's 2nd Largest Position

Stonepine Capital Management LLC decreased its position in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 7.7% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 1,264,651 shares of the company's stock after selling 105,170 shares during the period. Evolus accounts for approximately 11.3% of Stonepine Capital Management LLC's portfolio, making the stock its 2nd largest holding. Stonepine Capital Management LLC owned approximately 2.00% of Evolus worth $13,962,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. KBC Group NV acquired a new position in shares of Evolus during the 4th quarter valued at about $49,000. IFP Advisors Inc boosted its position in shares of Evolus by 17,440.7% in the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock worth $52,000 after acquiring an additional 4,709 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Evolus in the fourth quarter valued at approximately $106,000. Rafferty Asset Management LLC acquired a new position in Evolus during the fourth quarter worth approximately $115,000. Finally, Quantbot Technologies LP purchased a new position in Evolus during the fourth quarter worth approximately $118,000. Institutional investors and hedge funds own 90.69% of the company's stock.

Analyst Upgrades and Downgrades

EOLS has been the subject of several research reports. BTIG Research started coverage on shares of Evolus in a research note on Thursday, April 17th. They set a "buy" rating and a $21.00 price objective for the company. Barclays boosted their price target on Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Needham & Company LLC restated a "buy" rating and issued a $22.00 price objective on shares of Evolus in a report on Thursday, May 8th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $27.00 price objective on shares of Evolus in a research note on Thursday, April 10th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Evolus currently has an average rating of "Buy" and an average target price of $23.75.

Insider Activity at Evolus

In related news, Director Karah Herdman Parschauer sold 12,888 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $12.99, for a total transaction of $167,415.12. Following the transaction, the director now directly owns 32,183 shares of the company's stock, valued at approximately $418,057.17. The trade was a 28.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider David Moatazedi sold 6,251 shares of the company's stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $12.40, for a total value of $77,512.40. Following the completion of the transaction, the insider now owns 508,619 shares of the company's stock, valued at approximately $6,306,875.60. This represents a 1.21% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 86,241 shares of company stock worth $1,048,666. Corporate insiders own 5.90% of the company's stock.

Evolus Stock Up 0.2%

Shares of NASDAQ:EOLS traded up $0.02 during midday trading on Friday, hitting $9.58. 126,258 shares of the company's stock traded hands, compared to its average volume of 690,303. The firm's fifty day moving average price is $11.04 and its two-hundred day moving average price is $12.18. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. Evolus, Inc. has a twelve month low of $8.67 and a twelve month high of $17.82. The company has a market cap of $617.74 million, a PE ratio of -10.53 and a beta of 1.11.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.